Close

BIO Comments on New CMS Clinical Lab Fee Schedule Codes and Payment Determinations

Oct 4 2012
The Biotechnology Industry Organization (BIO) appreciates the opportunity to submit comments on the New and Reconsidered Clinical Laboratory Fee Schedule (CLFS) Test Codes and Preliminary Payment Determinations published by the Centers for Medicare and Medicaid Services (CMS) on August 31, 2012. BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnologies, thereby expanding the boundaries of science to benefit society by providing better healthcare, enhanced agriculture, and a cleaner and safer environment. Specifically related to advanced personalized diagnostic products, a number of BIO companies develop and market in vitro diagnostic technologies for a variety of research, investigational, and clinical uses. BIO is deeply concerned with CMS’ payment proposal regarding Multi-Analyte Assays with Algorithmic Analyses (MAAAs), and is concerned generally with the lack of transparency in the process through the annual CLFS meeting and publication of the proposed payment methodologies. BIO believes these proposed payments will threaten access to molecular pathology tests by Medicare beneficiaries and have a devastating impact on the advancement of personalized medicine.

CER: BIO’s comments on PCORI’s Draft Methodology Report

Sep 13 2012

...

Mexico's TPP Entry: BIO Submits Comments to USTR

Sep 4 2012
BIO supports the President’s decision to include Mexico in the TPP trade negotiations. Providing effective intellectual property protection for biological products is a central focus for BIO and its members.

Canada's Trans-Pacific Partnership (TPP) Entry: BIO Submits Comments to USTR

Sep 3 2012
The Government of Canada has long been a trusted ally to the United States on agricultural biotechnology. Canada has been a like minded partner in various international fora, including joining the United States government in a successful World Trade Organization

BIO's Comments to the CY 2013 Outpatient Prospective Payment System (OPPS) Proposed Rule

Sep 3 2012

...

Medicare Program: BIO's Comments on the Revisions to Payment Policies Under the Physician Fee Schedule and Other Revisions to Part B for Calendar Year 2013; Proposed Rule

Sep 3 2012

...

Biofuels Producers Coordinating Council Asks President Obama to Stay the Course on RFS

Aug 27 2012
We are writing to caution against granting a waiver for the federal Renewable Fuel Standard (RFS). A number of groups and some governors seem to believe that the RFS is a substantial part of the equation when it comes to grain prices, and waiving the program this year or next will ease the impact of the drought on consumers. There is substantial evidence to the contrary.

Medicaid: BIO's Comments on CMS's Draft NARP Methodology

Aug 16 2012

...

US-EU Working Group on Jobs and Growth: BIO Submits Comments on IP

Aug 16 2012

...

BIO Comments to CMS on Physician Payments Sunshine Act

Aug 14 2012
...